Mivebresib is an oral, small-molecule pan-BET inhibitor that induces cell death and tumor regression in animal models of malignancies such as myeloid leukemia [67], prostate cancer [68], and small cell lung cancer [69]. This evidence concerns the gene DNER and myeloid leukemia.